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Background
The fully human monoclonal antibodies nivolumab (Nivo)
and ipilimumab (Ipi) block the interaction between the
immune checkpoint receptors programmed death-1
(PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4),
respectively, and their cognate ligands, restoring antitumor
immune response. Phase 1 studies of Nivo monotherapy
(CA209-003; NCT00730639) or Nivo+Ipi combination
therapy (CA209-004; NCT01024231) demonstrated
durable clinical activity and objective response rates
(ORRs) of 31% to 40%, respectively, in patients with
advanced melanoma (MEL). Evaluation of PD-L1 expres-
sion using immunohistochemistry (IHC) suggested a cor-
relation between pretreatment tumor PD-L1 expression
and clinical response to Nivo monotherapy [1]. Identifica-
tion of predictive markers of response would be valuable
to guide effective use of Nivo and Ipi.
Materials and methods
MEL patients received Nivo monotherapy (n=107) or Nivo
+Ipi combination therapy (N=86; concurrent regimen:
n=53; sequenced regimen: n=33). Tumor and tumor infil-
trating lymphocyte (TIL) surface programmed death
ligand 1 (PD-L1) expression in formalin-fixed, paraffin-
embedded (FFPE) tumor tissue was evaluated by IHC with
an automated assay (Dako) using the 28-8 Ab. Tumor
PD-L1 positivity (PD-L1+) was defined as ≥5% cell
membrane staining of any intensity; any expression on
TILs was considered positive. Absolute lymphocyte counts
(ALC) were measured in serial peripheral blood samples
and lymphocyte subsets were evaluated using flow
cytometry.
Results
Tumor PD-L1-positive expression was observed in 45%
and 37% of samples from the 003 and 004 studies, respec-
tively. In 003, inclusion of any immune cell staining
increased PD-L1 positivity to 92%. A numerically higher
ORR was observed in MEL patients with PD-L1+ tumors
with Nivo monotherapy or with sequential but not con-
current combination therapy. Neither study demonstrated
an obvious change in ALC; however, phenotypic changes
in T-cell subsets, including increases in the percentage of
CD4 and CD8 expressing HLA-DR, ICOS and/or Ki67,
were seen with combination therapy. In both studies,
responses were observed irrespective of tumor PD-L1 or
ALC status. In an exploratory analysis low pretreatment
myeloid derived suppressor cells (MDSC) correlated with
higher ORR with combination therapy (P< 0.05).
Conclusions
PD-L1 positivity is associated with tumor response with
Nivo monotherapy; however, some responses were
observed independent of PD-L1 or ALC status. No cor-
relation between response and PD-L1 or ALC status
was seen with combination therapy. MDSC levels may
correlate with response to combination therapy. Future
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phase 3 randomized studies will explore these markers and
other phenotypic changes in immune cell populations that
might predict activity of Nivo in patients with MEL and
other advanced cancers.
Authors’ details
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 2Duke
University School of Medicine, Durham, NC, USA. 3The Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. 4Keck
School of Medicine, University of Southern California, Los Angeles, CA, USA.
5Bristol-Myers Squibb, Princeton, NJ, USA. 6Yale University School of
Medicine and Yale Cancer Center, New Haven, CT, USA.
Published: 6 May 2014
Reference
1. Topalian S, et al: N Engl J Med 2012, 366:2443-54.
doi:10.1186/1479-5876-12-S1-O8
Cite this article as: Postow et al.: Peripheral and tumor immune
correlates in patients with advanced melanoma treated with nivolumab
(anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination
with ipilimumab. Journal of Translational Medicine 2014 12(Suppl 1):O8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Postow et al. Journal of Translational Medicine 2014, 12(Suppl 1):O8
http://www.translational-medicine.com/content/12/S1/O8
Page 2 of 2
